Indivior Has Cleaned Up the Balance Sheet and Re-accelerated Growth — Time to Buy the Rally

Hook & thesis

I first covered Indivior when the company was still digging out from a long legal and restructuring cycle. The story has meaningfully changed: SUBLOCADE sales are scaling, management raised 2026 guidance, and the company just completed a convertible notes package that repays more expensive debt and funds buybacks. For traders comfortable with mid-term swings, INDV at $37.50 looks like a buy — not a speculative punt but a directional, event-driven trade backed by improving revenue and tighter capital structure.

Put simply: growth is visible and the balance sheet is cleaner. That combination narrows execution risk and makes upside easier to justify from a valuation standpoint.

Business summary - what Indivior actually does and why the market should care

Indivior is a specialty pharmaceutical company focused on opioid use disorder (OUD). The growth engine is SUBLOCADE, a monthly injectable buprenorphine product for OUD that management is pushing into broader clinical and institutional settings. Monthly injectables address adherence and reduce overdose risk relative to some other therapies, and the company is building clinical and real-world evidence to support better outcomes - a direct commercial lever.

For investors the driver is straightforward: if SUBLOCADE keeps growing at double-digit rates and the company executes on cost saves and smarter capital structure moves, revenues and margins can absorb modest dilution or financing costs and still create shareholder value.

What the numbers show

Concrete datapoints tell the story:

• Q1 revenue was $317 million, up 19% year-over-year, with SUBLOCADE sales of $232 million, a 32% increase - clear evidence the core product is scaling.
• Management issued 2026 guidance of $1,125 - $1,195 million in total net revenue and SUBLOCADE net revenue guidance of $905 - $945 million, implying continued high-single to double-digit growth for the franchise.
• Valuation is not frothy: market capitalization sits around $4.66 billion, price-to-earnings roughly 17.6-18.9 depending on the series of reported metrics, price-to-sales ~3.42, EV/EBITDA ~13.9 and enterprise value near $4.73 billion. Those multiples are reasonable versus a mid-teens growth profile and improving margin trajectory.
• Balance sheet and capital moves: Indivior priced an upsized $450 million convertible senior notes offering (0.625% due 2031, conversion price ~$41.66) and plans to use proceeds to repay about $239 million of term loan/revolver debt, repurchase roughly 2.4 million shares (~$75 million) and otherwise fund operations. That refinancing replaces higher-cost debt and signals management is prioritizing de-levering and shareholder return.

Valuation framing

At a market cap near $4.66 billion and enterprise value near $4.73 billion, Indivior is trading at a P/E around 17-19 and EV/EBITDA ~13.9. Those metrics look reasonable given the company's growth in SUBLOCADE: management guidance implies full-year SUBLOCADE sales of about $905 - $945 million, meaning the drug alone could represent roughly 75-80% of total revenue in 2026 if guidance holds.

Because the business is a single-product-driven growth story, traditional peer comps are imperfect. But compared to higher-risk specialty pharma names that still lack scale, INDV's multiples fit a company transitioning from recovery into stable profitable growth. The convertible notes dilute only if converted at a ~35% premium to current price, and planned buybacks offset some dilution — a balanced capital plan.

Technicals and market context

Technically the stock is in a constructive zone: current price $37.50 sits above the 50-day SMA ($34.93) and near the 20-day SMA ($37.01), RSI ~55 indicates no exhaustion, and volume has been elevated recently. Short interest has been meaningful (recent settlement ~13.7 million shares), which can amplify moves in either direction but also suggests a possible squeeze dynamic if headlines remain positive.

Trade plan - actionable entry, target, stop and horizon

My trade is directional long with a mid-term time frame: mid term (45 trading days). I expect the trade to play out as the market digests Q2 cadence, the refinancing benefits become clearer in interest expense, and further real-world evidence continues to support SUBLOCADE adoption.

• Entry price: $37.50
• Target price: $46.00
• Stop loss: $33.00
• Risk level: Medium

Rationale: $46.00 is reachable in the next 30-45 trading days if SUBLOCADE growth and macro appetite for healthcare names remain intact; it implies ~22.7% upside. The $33 stop sits below the 50-day SMA and gives room for normal volatility while limiting downside to ~12% from entry.

Catalysts to push this trade higher

• Continued SUBLOCADE sales beat: quarterly prints or interim commercial updates that extend the 32% Q1 growth would buttress higher estimates.
• Positive real-world data acceptance and adoption - the ASAM presentations and any follow-up adoption evidence that lower overdose incidence relative to competitors is replicable.
• Visible interest expense reduction or improved liquidity following the convertible notes refinancing (priced 03/13/2026) and repayment of higher-cost loans.
• Share repurchase execution that meaningfully offsets potential conversion dilution and signals confidence from the buyback program.

Risks and counterarguments

Every trade has risks. Here are the most important ones to monitor:

• Regulatory and legal risk - pharmaceutical companies face litigation and regulatory hurdles. Any adverse rulings or unexpected regulatory findings could quickly pressure the stock.
• Reimbursement pressure - adoption of SUBLOCADE depends on payer policies and institutional uptake; slower-than-expected formulary wins would hurt sales.
• Balance sheet & liquidity - current ratio ~0.86 and quick ratio ~0.66 indicate tighter near-term liquidity. While the convertible deal reduces debt burdens, cash management remains essential and negative free cash flow (-$193 million) is a flag to watch.
• Dilution from conversion - the convertible notes convert at ~$41.66 a share; a conversion event or heavy issuance could be dilutive if not offset by repurchases.
• Execution risk on commercial expansion - growing SUBLOCADE sales requires sales execution and provider buy-in; execution missteps would slow revenue momentum.
• Market risk / sentiment - macro risk or a risk-off shift in healthcare stocks could pull INDV down even with company-level progress; short interest can amplify these moves.

Counterargument: A skeptical view is that INDV's upside is already priced in after the recent run (stock is close to its 52-week high of $41.00), and that remaining legal, reimbursement or execution risks make the valuation less attractive. This is fair: if Q2 or subsequent quarters disappoint, multiple contraction could be swift. That is why the trade uses a strict $33 stop and a mid-term horizon rather than a buy-and-hold stance.

What would change my mind

I would downgrade this trade if any of the following happen: a material miss in SUBLOCADE revenue or guidance, a negative regulatory/legal development tied to the product, tangible evidence that payers are restricting access to monthly injectables, or fresh liquidity stress indicators (e.g., covenant breaches or inability to roll short-term debt). Conversely, sustained sequential beats and evidence that buybacks are offsetting dilution would strengthen my conviction and push me to target a longer time horizon.

Conclusion

Indivior is a different company than it was a few years ago. The growth engine (SUBLOCADE) is delivering double-digit growth, management raised 2026 guidance, and the convertible notes refinancing is a pragmatic balance between debt repayment and shareholder return. For the mid-term swing trader, INDV at $37.50 is a reasonable long with a $46 target and a $33 stop — a trade that buys improving fundamentals and a cleaner capital structure while protecting against the main downside scenarios.

Trade plan recap: Buy INDV at $37.50, target $46.00, stop $33.00. Horizon: mid term (45 trading days). Risk level: medium.